NEW YORK (
CHANGE IN RATINGS
rated new Hold at ThinkEquity. $30 price target. Execution risk remains high, because of increased competition.
rated new Buy at ThinkEquity. $44 price target. Company has a growing commercial franchise and a deep pipeline.
downgraded at Oppenheimer to Perform from Outperform, Oppenheimer said. Low coverage ratio.
upgraded at Argus from Hold to Buy, Argus Research said. $75 price target. Stock appears oversold, following a 20% decline.
upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Healthcare reform should help hospitals expand margins.
downgraded at BofA/Merrill from Neutral to Underperform, Bank of America/Merrill Lynch said. $10 price target. Company has lost some top managers and growth is slowing in regional markets.
Enbridge Energy Partners
upgraded at Oppenheimer to Outperform from Perform, Oppenheimer said. $36 price target. Attractive growth outlook.
( LNCR) upgraded at Jefferies to Buy from Hold, Jefferies said. $38 price target. Risk-reward has improved.
upgraded at BofA/Merrill to Buy, Bank of America/Merrill Lynch said. $57 price target. Company is seeing higher prices and sales and using new summer initiatives.
downgraded at Baird to Neutral. $85 price target. Stronger dollar and slower growth in China are hurting margins.
Nike downgraded at Sterne Agee to Neutral. Estimates also cut, given slower growth, especially in China.
Nike downgraded at DA Davidson to Neutral. $93 price target. Company faces growth headwinds and lowered guidance.
upgraded at JP Morgan from Neutral to Overweight, JP Morgan said. $12 price target. Company has mutli-year sales and margin growth drivers in place.
downgraded at Citigroup to Neutral from Buy, Citigroup said. $10 price target. Macro will be a headwind to margin expansion.
rated new Buy at Goldman. $73 price target. Company has multiple growth drivers, including the recent Vought acquisition.
upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Valuation call, relative to the group.
downgraded at Wells from Outperform to Market Perform, Wells Fargo said. Valuation call, as other names offer better upside potential.
downgraded at Sterne Agee to Neutral, Sterne Agee said. Valuation call, as the stock is up 23% over the past year.
STOCK COMMENTS / EPS CHANGES
estimates, target cut at Credit Suisse. Shares of ACN now seen reaching $61, according to Credit Suisse. Estimates also reduced, given the company's exposure to Europe and Financial Services. Neutral rating.
Accenture numbers lowered at Jefferies. Shares of ACN now seen reaching $60, Jefferies said. Estimates also lowered on more deceleration ahead. Hold rating.
numbers cut at Morgan Stanley. Shares of F now seen reaching $17, according to Morgan Stanley. Estimates also reduced, given slower growth in Europe. Overweight rating.
Ford numbers cut at UBS. Shares of F now seen reaching $15, UBS said. Estimates also lowered as international losses drag down 2Q. Buy rating.
estimates, target reduced at Credit Suisse. NKE estimates were cut through 2013, Credit Suisse said. Company is realizing lower margins. Neutral rating and new $93 price target.
Nike numbers cut at UBS. Shares of NKE now seen reaching $99, UBS said. Estimates also lowered as worrisome China and gross margins reflect global challenges. Buy rating.
Research in Motion
( RIMM) numbers reduced at Credit Suisse. RIMM estimates were cut through 2014, Credit Suisse said. Company needs further restructuring. Neutral rating and new $7 price target.
Research in Motion numbers lowered at UBS.Shares of RIMM now seen reaching $10.50, UBS said. Estimates also lowered as there are no catalysts for next two quarters. Neutral rating.
Research in Motion numbers cut at Citigroup. Shares of RIMM now seen reaching $5, Citigroup said. Estimates also lowered on delay of BB10. Sell rating.
target boosted at BMO to $105, according to BMO Capital. Sales remain robust and the clear market leader deserves a premium valuation.
numbers cut at UBS. Shares of WLT now seen reaching $75, UBS said. Estimates also lowered at 2Q pre guide disappoints. Buy rating.
target raised at Citigroup to $78, Citigroup said. Well positioned to benefit in current macro environment. Buy rating.
>To submit a news tip, email:
READERS ALSO LIKE:
and become a fan on
This article was written by a staff member of TheStreet.